Cargando…
Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan
Limited real-world data are available regarding treatment practices and outcomes of multiple myeloma (MM) in Asia. We conducted a retrospective cohort study using the Taiwan National Healthcare Insurance Research database and Taiwan Death Registry and used a Markov model to describe disease progress...
Autores principales: | Liu, Yanfang, Tang, Chao-Hsiun, Qiu, Hong, Siggins, Sarah, Hou, Hsin-An |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806818/ https://www.ncbi.nlm.nih.gov/pubmed/33441901 http://dx.doi.org/10.1038/s41598-020-80607-4 |
Ejemplares similares
-
Treatment evolution and improved survival in multiple myeloma in Taiwan
por: Tang, Chao-Hsiun, et al.
Publicado: (2019) -
Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan
por: Liu, Yanfang, et al.
Publicado: (2020) -
A population-based cohort study of the epidemiology of light-chain amyloidosis in Taiwan
por: Hou, Hsin-An, et al.
Publicado: (2022) -
Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019) -
Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)